{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:30:38Z","timestamp":1790303438274,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T00:00:00Z","timestamp":1542240000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00213-018-5101-7","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T11:48:40Z","timestamp":1542282520000},"page":"723-730","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study"],"prefix":"10.1007","volume":"236","author":[{"given":"Bunta","family":"Yoshimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Tsukahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusaku","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuhei","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,15]]},"reference":[{"key":"5101_CR1","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TR Barnes","year":"1989","unstructured":"Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672\u2013676","journal-title":"Br J Psychiatry"},{"key":"5101_CR2","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1192\/bjp.161.6.791","volume":"161","author":"TR Barnes","year":"1992","unstructured":"Barnes TR, Halstead SM, Little PW (1992) Relationship between iron status and chronic akathisia in an in-patient population with chronic schizophrenia. Br J Psychiatry 161:791\u2013796","journal-title":"Br J Psychiatry"},{"issue":"4","key":"5101_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/00004850-200015040-00004","volume":"15","author":"D Berardi","year":"2000","unstructured":"Berardi D, Giannelli A, Barnes TR (2000) Clinical correlates of akathisia in acute psychiatric inpatients. Int Clin Psychopharmacol 15(4):215\u2013219","journal-title":"Int Clin Psychopharmacol"},{"key":"5101_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"RW Buchanan","year":"2010","unstructured":"Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36:71\u201393","journal-title":"Schizophr Bull"},{"issue":"19","key":"5101_CR5","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1056\/NEJMra1401038","volume":"372","author":"C Camaschella","year":"2015","unstructured":"Camaschella C (2015) Iron-deficiency anemia. N Engl J Med 372(19):1832\u20131843","journal-title":"N Engl J Med"},{"issue":"5","key":"5101_CR6","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jnnp.2006.101014","volume":"78","author":"PE Cotter","year":"2007","unstructured":"Cotter PE, O'Keeffe ST (2007) Improvement in neuroleptic-induced akathisia with intravenous iron treatment in a patient with iron deficiency. J Neurol Neurosurg Psychiatry 78(5):548","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"5101_CR7","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.4088\/JCP.v67n1004","volume":"67","author":"B Crespo-Facorro","year":"2006","unstructured":"Crespo-Facorro B, P\u00e9rez-Iglesias R, Ramirez-Bonilla M, Mart\u00ednez-Garc\u00eda O, Llorca J, Luis V\u00e1zquez-Barquero J (2006) A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry 67(10):1511\u20131521","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"5101_CR8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00213-013-3241-3","volume":"231","author":"B Crespo-Facorro","year":"2014","unstructured":"Crespo-Facorro B, de la Foz VO, Mata I, Ayesa-Arriola R, Suarez-Pinilla P, Valdizan EM, Martinez-Garcia O et al (2014) Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year. Psychopharmacology 231(2):357\u2013366","journal-title":"Psychopharmacology"},{"issue":"5","key":"5101_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0004867416641195","volume":"50","author":"C Galletly","year":"2016","unstructured":"Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, Kulkarni J, McGorry P, Nielssen O, Tran N (2016) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 50(5):410\u2013472","journal-title":"Aust N Z J Psychiatry"},{"issue":"6","key":"5101_CR10","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","volume":"167","author":"DM Gardner","year":"2010","unstructured":"Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167(6):686\u2013693","journal-title":"Am J Psychiatry"},{"issue":"7","key":"5101_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/hup.325","volume":"16","author":"L Hansen","year":"2001","unstructured":"Hansen L (2001) A critical review of akathisia, and its possible association with suicidal behaviour. Hum Psychopharmacol 16(7):495\u2013505","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"5101_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hup.2305","volume":"28","author":"LK Hansen","year":"2013","unstructured":"Hansen LK, Nausheen B, Hart D, Kingdon D (2013) Movement disorders in patients with schizophrenia and a history of substance abuse. Hum Psychopharmacol 28(2):192\u2013197","journal-title":"Hum Psychopharmacol"},{"issue":"1\u201302","key":"5101_CR13","first-page":"9","volume":"51","author":"C Hiemke","year":"2017","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K et al (2017) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51(1\u201302):9\u201362","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"5101_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0165-1781(00)00115-3","volume":"93","author":"M Hofmann","year":"2000","unstructured":"Hofmann M, Seifritz E, Botschev C, Kr\u00e4uchi K, M\u00fcller-Spahn F (2000) Serum iron and ferritin in acute neuroleptic akathisia. Psychiatry Res 93(3):201\u2013207","journal-title":"Psychiatry Res"},{"issue":"3","key":"5101_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1600-0447.1991.tb03148.x","volume":"84","author":"J Horiguchi","year":"1991","unstructured":"Horiguchi J (1991) Low serum iron in patients with neuroleptic-induced akathisia and dystonia under antipsychotic drug treatment. Acta Psychiatr Scand 84(3):301\u2013303","journal-title":"Acta Psychiatr Scand"},{"key":"5101_CR16","volume-title":"Evaluation and diagnosis of drug-induced extrapyramidal symptoms: commentary on the DIEPSS and guide to its usage","author":"T Inada","year":"1996","unstructured":"Inada T (1996) Evaluation and diagnosis of drug-induced extrapyramidal symptoms: commentary on the DIEPSS and guide to its usage. Seiwa Shoten, Tokyo"},{"key":"5101_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/0924-977X(96)87599-7","volume":"6","author":"T Inada","year":"1996","unstructured":"Inada T, Yagi G, Gardos G (1996) Inter-rater reliability of the drug-induced extrapyramidal symptoms scale (DIEPSS). Eur Neuropsychopharmacol 6:64","journal-title":"Eur Neuropsychopharmacol"},{"key":"5101_CR18","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1192\/bjp.166.5.654","volume":"166","author":"SH Jones","year":"1995","unstructured":"Jones SH, Thornicroft G, Coffey M, Dunn G (1995) A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 166:654\u2013659","journal-title":"Br J Psychiatry"},{"issue":"1","key":"5101_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1751-7893.2010.00163.x","volume":"4","author":"RC Josiassen","year":"2010","unstructured":"Josiassen RC, Shaughnessy RA, Filymer DM, Donohue AM, Kacso M, Finkel N, Skuban N et al (2010) Early intervention with second-generation antipsychotics in first-episode psychosis: results of an 8-week naturalistic study. Early Interv Psychiatry 4(1):57\u201363","journal-title":"Early Interv Psychiatry"},{"issue":"17","key":"5101_CR20","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1007\/s00213-017-4646-1","volume":"234","author":"M Juncal-Ruiz","year":"2017","unstructured":"Juncal-Ruiz M, Ramirez-Bonilla M, Gomez-Arnau J, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, Martinez-Garcia O, Neergaard KD et al (2017) Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. Psychopharmacology 234(17):2563\u20132570","journal-title":"Psychopharmacology"},{"issue":"9618","key":"5101_CR21","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD et al (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371(9618):1085\u20131097","journal-title":"Lancet"},{"issue":"5","key":"5101_CR22","doi-asserted-by":"publisher","first-page":"627","DOI":"10.4088\/JCP.08r04210","volume":"70","author":"JM Kane","year":"2009","unstructured":"Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A 3rd, Assun\u00e7\u00e3o-Talbott S (2009) Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 70(5):627\u2013643","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"5101_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1365-2710.2007.00848.x","volume":"32","author":"JH Kim","year":"2007","unstructured":"Kim JH, Byun HJ (2007) Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol. J Clin Pharm Ther 32(5):461\u2013467","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"5101_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0924-977X(02)00073-1","volume":"13","author":"M Kuloglu","year":"2003","unstructured":"Kuloglu M, Atmaca M, Ust\u00fcndag B, Canatan H, Gecici O, Tezcan E (2003) Serum iron levels in schizophrenic patients with or without akathisia. Eur Neuropsychopharmacol 13(2):67\u201371","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"5101_CR25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.64719\/pb.4321","volume":"41","author":"A Maat","year":"2008","unstructured":"Maat A, Fouwels A, de Haan L (2008) Cocaine is a major risk factor for antipsychotic induced akathisia, parkinsonism and dyskinesia. Psychopharmacol Bull 41(3):5\u201310","journal-title":"Psychopharmacol Bull"},{"issue":"7","key":"5101_CR26","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1176\/ajp.2007.164.7.1050","volume":"164","author":"JP McEvoy","year":"2007","unstructured":"McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D et al (2007) Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164(7):1050\u20131060","journal-title":"Am J Psychiatry"},{"issue":"11","key":"5101_CR27","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2165\/00023210-200216110-00008","volume":"16","author":"JK McGavin","year":"2002","unstructured":"McGavin JK, Goa KL (2002) Aripiprazole. CNS Drugs 16(11):779\u2013786","journal-title":"CNS Drugs"},{"issue":"1","key":"5101_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0924-977X(96)00041-7","volume":"7","author":"CH Miller","year":"1997","unstructured":"Miller CH, Hummer M, Oberbauer H, Kurzthaler I, DeCol C, Fleischhacker WW (1997) Risk factors for the development of neuroleptic induced akathisia. Eur Neuropsychopharmacol 7(1):51\u201355","journal-title":"Eur Neuropsychopharmacol"},{"key":"5101_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/HRP.0b013e31827fd915","volume":"21","author":"DN Osser","year":"2013","unstructured":"Osser DN, Roudsari MJ, Manschreck T (2013) The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harv Rev Psychiatry 21:18\u201340","journal-title":"Harv Rev Psychiatry"},{"issue":"2\u20133","key":"5101_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.schres.2009.06.010","volume":"113","author":"S Potvin","year":"2009","unstructured":"Potvin S, Blanchet P, Stip E (2009) Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis. Schizophr Res 113(2\u20133):181\u2013188","journal-title":"Schizophr Res"},{"issue":"2","key":"5101_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1192\/bjp.bp.109.070540","volume":"196","author":"M Poyurovsky","year":"2010","unstructured":"Poyurovsky M (2010) Acute antipsychotic-induced akathisia revisited. Br J Psychiatry 196(2):89\u201391","journal-title":"Br J Psychiatry"},{"key":"5101_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1176\/appi.ajp.2014.13101355","volume":"172","author":"DG Robinson","year":"2015","unstructured":"Robinson DG, Schooler NR, John M, Correll CU, Marcy P, Addington J, Brunette MF, Estroff SE, Mueser KT, Penn D, Robinson J, Rosenheck RA, Severe J, Goldstein A, Azrin S, Heinssen R, Kane JM (2015) Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry 172:237\u2013248","journal-title":"Am J Psychiatry"},{"issue":"3","key":"5101_CR33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/schbul\/21.3.431","volume":"21","author":"P Sachdev","year":"1995","unstructured":"Sachdev P (1995a) The epidemiology of drug-induced akathisia: part I. Acute akathisia. Schizophr Bull 21(3):431\u2013449","journal-title":"Schizophr Bull"},{"issue":"3","key":"5101_CR34","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/schbul\/21.3.451","volume":"21","author":"P Sachdev","year":"1995","unstructured":"Sachdev P (1995b) The epidemiology of drug-induced akathisia: part II. Chronic, tardive, and withdrawal akathisias. Schizophr Bull 21(3):451\u2013461","journal-title":"Schizophr Bull"},{"issue":"5","key":"5101_CR35","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1176\/appi.ajp.162.5.947","volume":"162","author":"N Schooler","year":"2005","unstructured":"Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, De Smedt G et al (2005) Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatr 162(5):947\u2013953","journal-title":"Am J Psychiatr"},{"issue":"5","key":"5101_CR36","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/JCP.0b013e3182677958","volume":"32","author":"F Seem\u00fcller","year":"2012","unstructured":"Seem\u00fcller F, Schennach R, Mayr A, Musil R, J\u00e4ger M, Maier W, Klingenberg S, Heuser I, Klosterk\u00f6tter J, Gastpar M, Schmitt A, Schl\u00f6sser R, Schneider F, Ohmann C, Lewitzka U, Gaebel W, M\u00f6ller HJ, Riedel M (2012) Akathisia and suicidal ideation in first-episode schizophrenia. J Clin Psychopharmacol 32(5):694\u2013698","journal-title":"J Clin Psychopharmacol"},{"key":"5101_CR37","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1192\/bjp.163.5.669","volume":"163","author":"SD Soni","year":"1993","unstructured":"Soni SD, Tench D, Routledge RC (1993) Serum iron abnormalities in neuroleptic-induced akathisia in schizophrenic patients. Br J Psychiatry 163:669\u2013672","journal-title":"Br J Psychiatry"},{"issue":"6","key":"5101_CR38","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1600-0447.2008.01183.x","volume":"117","author":"S Sundram","year":"2008","unstructured":"Sundram S, Lambert T, Piskulic D (2008) Acculturation is associated with the prevalence of tardive dyskinesia and akathisia in community-treated patients with schizophrenia. Acta Psychiatr Scand 117(6):474\u2013478","journal-title":"Acta Psychiatr Scand"},{"key":"5101_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5234\/cnpt.3.3","volume":"3","author":"M Takaki","year":"2012","unstructured":"Takaki M, Yoshimura B (2012) High doses or rapid dose escalation of aripiprazole may be more effective for treating schizophrenia. Clin Neuropsychopharmacol Ther 3:3\u20134","journal-title":"Clin Neuropsychopharmacol Ther"},{"key":"5101_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2017.08.012","volume":"193","author":"H Takeuchi","year":"2018","unstructured":"Takeuchi H, Thiyanavadivel S, Agid O, Remington G (2018) Rapid vs. slow antipsychotic initiation in schizophrenia: a systematic review and meta-analysis. Schizophr Res 193:29\u201336","journal-title":"Schizophr Res"},{"key":"5101_CR41","first-page":"218","volume-title":"ECDEU assessment manual for psychopharmacology, revised. 36","author":"US Dept Health, Education, and Welfare","year":"1976","unstructured":"US Dept Health, Education, and Welfare (1976) Clinical global impression (CGI) scale. In: Guy W (ed) ECDEU assessment manual for psychopharmacology, revised. 36. US Dept Health, Education, and Welfare, Washington, DC, pp 218\u2013222"},{"key":"5101_CR42","first-page":"112","volume":"24","author":"MG Woerner","year":"1988","unstructured":"Woerner MG, Mannuzza S, Kane JM (1988) Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull 24:112\u2013117","journal-title":"Psychopharmacol Bull"},{"key":"5101_CR43","doi-asserted-by":"publisher","unstructured":"Yoshimura B, Sato K, Takaki M, Yamada N (2017) Algorithm-based pharmacotherapy for first-episode schizophrenia involuntarily hospitalized: a retrospective analysis of real-world practice. Early Interv Psychiatry. https:\/\/doi.org\/10.1111\/eip.12442","DOI":"10.1111\/eip.12442"},{"issue":"6","key":"5101_CR44","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1017\/S1461145712001277","volume":"16","author":"JP Zhang","year":"2013","unstructured":"Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU (2013) Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol 16(6):1205\u20131218","journal-title":"Int J Neuropsychopharmacol"},{"issue":"9","key":"5101_CR45","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2215-0366(17)30270-5","volume":"4","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Krause M, Huhn M, Rothe P, Schneider-Thoma J, Chaimani A, Li C, Davis JM, Leucht S (2017) Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry 4(9):694\u2013705","journal-title":"Lancet Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-018-5101-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-018-5101-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-018-5101-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T02:28:11Z","timestamp":1775269691000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-018-5101-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,15]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["5101"],"URL":"https:\/\/doi.org\/10.1007\/s00213-018-5101-7","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,15]]},"assertion":[{"value":"14 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Institutional Review Board of our hospital approved this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Yoshimura has received honoraria for his participation as a speaker at educational events sponsored by Janssen. Dr. Sato has received honoraria for his participation as a speaker at educational events sponsored by Otsuka, Janssen, and Dainippon-Sumitomo. Dr. Sakamoto has received unrestricted research funding from Eli Lilly, which was deposited into research accounts at Okayama University Hospital. Dr. Sakamoto has received honoraria for his participation as a speaker at an educational event sponsored by Otsuka. Dr. Tsukahara, and Dr. So report no additional financial or other relationship relevant to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}